An interventional study of Magnetic Resonance Imaging and Questionnaire Administration in Prostate Carcinoma, Stage I Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, sponsored by Emory University. Recruiting at 3 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Emory University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Prostatic Neoplasms by Emory University — 7 open to participants now, 9 under way, 1 of them phase 3. Prostatic Neoplasms · Emory University.
Among the 25 studies in Prostatic Neoplasms by Emory University, this one is the 5th largest by planned enrollment, is one of 2 that started in 2026, is one of 10 with no phase, and was the 25th registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →7 of the 25 studies in Prostatic Neoplasms by Emory University are open now, in 1 country. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Emory University · Sites in United States
Ages 25–100 · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 2
First in 2003; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 30 across the 25 interventional studies. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
2 of the studies in Prostatic Neoplasms by Emory University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04725903Emory UniversityProton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer | 2026-12-31 |
| NCT03322891Emory UniversityImproving Health Literacy in African-American Prostate Cancer Patients | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 25 studies in Prostatic Neoplasms by Emory University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial studies the safety of a computed tomography (CT) scan, with or without a magnetic resonance imaging (MRI) scan, in planning for high-dose-rate (HDR) prostate brachytherapy treatment in patients with prostate cancer. Brachytherapy is a type of radiation therapy in which radioactive implants, such as pellets, seeds, ribbons, wires, needles, balloons, or capsules, are placed in the body, directly into or near the tumor. The radiation is delivered through a flexible tube called a catheter or a larger device called an applicator. Treatment planning, or simulation, is a process used to plan radiation therapy so that the target area is precisely located and marked. A CT scan is a procedure that uses a computer linked to an x-ray machine to make a series of detailed pictures of areas inside the body. The pictures are taken from different angles and are used to create 3-dimensional views of tissues and organs. An MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. The addition of MRI to CT for HDR prostate brachytherapy treatment planning may help patients have less urine leakage and less pain after treatment.
PRIMARY OBJECTIVE:
I. To compare acute changes in patient reported outcomes of urinary toxicity utilizing the Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
SECONDARY OBJECTIVES:
I. To compare acute and chronic changes in patient reported outcomes of toxicity utilizing the EPIC-26 Urinary Irritative/Obstructive, Bowel, and Sexual domain scores for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
II. To compare the cumulative incidence of physician reported Common Terminology Criteria for Adverse Events (CTCAE) acute and chronic grade 2+ genitourinary (GU) or gastrointestinal (GI) toxicity for patients undergoing prostate HDR brachytherapy planned with utilization of an MRI versus no MRI.
TERTIARY/EXPLORATORY OBJECTIVE:
I. To compare treatment efficacy for patients undergoing prostate HDR brachytherapy planned with the utilization of an MRI versus no MRI.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo treatment planning with a CT scan for HDR brachytherapy.
ARM B: Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.
After completion of study intervention, patients are followed up at 1, 3, 6, and 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo treatment planning with a CT scan for HDR brachytherapy.
Other: Questionnaire Administration
Patients undergo treatment planning with a CT scan and MRI scan for HDR brachytherapy.
Procedure: Magnetic Resonance Imaging · Other: Questionnaire Administration
Undergo MRI scan
Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
Ancillary studies
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
The primary analysis will be conducted using a mixed-effects model for repeated measures (MMRM) including fixed effects for treatment arm, categorical time, treatment-by-time interaction, baseline Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence score, age, comorbidity status, and the stratification factors of high-dose-rate treatment approach and rectal spacer use. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother. The primary treatment comparison will be the adjusted between-group difference at the 1-month time point derived from the treatment-by-time interaction using least-squares means, with corresponding two-sided 95% confidence intervals and p-values evaluated at a significance level of 0.05.
Time frame: At 1 month following treatment
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Incontinence domain score
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary incontinence scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother.
Time frame: At 3, 6 and 12 months following treatment
Mean Expanded Prostate Cancer Index Composite-26 (EPIC-26) Urinary Irritative/Obstructive, Bowel, and Sexual domain scores
Longitudinal analyses of Expanded Prostate Cancer Index Composite-26 (EPIC-26) urinary irritative/obstructive, bowel, and sexual domain scores will be conducted using MMRM models analogous to the primary analysis, including the stratification factors as covariates. Adjusted mean scores and between-group differences at each time point will be reported with 95% confidence intervals. EPIC-26 scores range 0-100 with higher scores meaning improved function or lower symptom bother.
Time frame: At 1, 3, 6 and 12 months following treatment
Cumulative incidence of grade 2 or higher genitourinary or gastrointestinal adverse events
Will be analyzed using competing-risk methods to account for death as a competing event. Cumulative incidence functions will be estimated for each treatment arm and compared using Gray's test. Fine-Gray subdistribution hazard models, including stratification factors and relevant covariates, will be used to estimate adjusted hazard ratios with 95% confidence intervals. Adverse events will be coded using the Medical Dictionary for Regulatory Activities and graded according to Common Terminology Criteria for Adverse Events version 5.0. Safety analyses will summarize the frequency, severity, and relationship of adverse events to study treatment by System Organ Class and preferred term. Each adverse event will be counted once per participant at the maximum severity grade. Serious adverse events and events leading to treatment discontinuation will be summarized separately.
Time frame: Within 12 months following treatment
Started Oct 2026 (actual). Primary completion is estimated for May 2028, 19 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 19 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
Start moved once since we started tracking on Sep 25, 2026: Nov 2026 → Oct 2026, on Nov 2, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.